Editorial on “Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer”

Most urologists who treat prostate cancer (PCa) patients are familiar with the well-known Briganti nomograms. According to the EAU guidelines on PCa (1), the indications for nodal sampling by means of extended pelvic lymph nodes (LNs) dissection (ePLND) are high-risk and intermediate-risk PCa with a risk of nodal metastases of over 5% according to the Briganti nomogram or MSKCC (2-4).